-
1
-
-
27244445489
-
Molecular pathogenesis and a consequent classification of multiple myeloma
-
DOI 10.1200/JCO.2005.05.021
-
Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333-6338. (Pubitemid 46218843)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.26
, pp. 6333-6338
-
-
Bergsagel, P.L.1
Kuehl, W.M.2
-
2
-
-
74049162897
-
International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review
-
Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
-
(2009)
Leukemia
, vol.23
, pp. 2210-2221
-
-
Fonseca, R.1
Bergsagel, P.L.2
Drach, J.3
Shaughnessy, J.4
Gutierrez, N.5
Stewart, A.K.6
-
3
-
-
84856706335
-
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC Myeloma IX trial
-
Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012; 26: 349-355.
-
(2012)
Leukemia
, vol.26
, pp. 349-355
-
-
Boyd, K.D.1
Ross, F.M.2
Chiecchio, L.3
Dagrada, G.P.4
Konn, Z.J.5
Tapper, W.J.6
-
5
-
-
31744438381
-
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
-
DOI 10.1038/sj.onc.1208989, PII 1208989
-
Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, Duclos N et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 2005; 24: 8259-8267. (Pubitemid 43250918)
-
(2005)
Oncogene
, vol.24
, Issue.56
, pp. 8259-8267
-
-
Chen, J.1
Lee, B.H.2
Williams, I.R.3
Kutok, J.L.4
Mitsiades, C.S.5
Duclos, N.6
Cohen, S.7
Adelsperger, J.8
Okabe, R.9
Coburn, A.10
Moore, S.11
Huntly, B.J.P.12
Fabbro, D.13
Anderson, K.C.14
Griffin, J.D.15
Gilliland, D.G.16
-
6
-
-
33646555792
-
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
-
DOI 10.1182/blood-2005-10-4179
-
Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006; 107: 4039-4046. (Pubitemid 43726812)
-
(2006)
Blood
, vol.107
, Issue.10
, pp. 4039-4046
-
-
Trudel, S.1
Stewart, A.K.2
Rom, E.3
Wei, E.4
Zhi, H.L.5
Kotzer, S.6
Chumakov, I.7
Singer, Y.8
Chang, H.9
Liang, S.-B.10
Yayon, A.11
-
7
-
-
79952123613
-
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
-
Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011; 117: 2396-2404.
-
(2011)
Blood
, vol.117
, pp. 2396-2404
-
-
Annunziata, C.M.1
Hernandez, L.2
Davis, R.E.3
Zingone, A.4
Lamy, L.5
Lam, L.T.6
-
8
-
-
22044440425
-
Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma
-
DOI 10.1182/blood-2005-01-0034
-
Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303. (Pubitemid 40967205)
-
(2005)
Blood
, vol.106
, Issue.1
, pp. 296-303
-
-
Bergsagel, P.L.1
Kuehl, W.M.2
Zhan, F.3
Sawyer, J.4
Barlogie, B.5
Shaughnessy Jr., J.6
-
9
-
-
78650174738
-
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial
-
Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989-1999.
-
(2010)
Lancet
, vol.376
, pp. 1989-1999
-
-
Morgan, G.J.1
Davies, F.E.2
Gregory, W.M.3
Cocks, K.4
Bell, S.E.5
Szubert, A.J.6
-
10
-
-
0037441747
-
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
-
DOI 10.1182/blood-2002-06-1675
-
Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 2003; 101: 1520-1529. (Pubitemid 36182529)
-
(2003)
Blood
, vol.101
, Issue.4
, pp. 1520-1529
-
-
Keats, J.J.1
Reiman, T.2
Maxwell, C.A.3
Taylor, B.J.4
Larratt, L.M.5
Mant, M.J.6
Belch, A.R.7
Pilarski, L.M.8
-
11
-
-
33750327901
-
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
-
DOI 10.1038/sj.leu.2404403, PII 2404403
-
Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006; 20: 2034-2040. (Pubitemid 44614894)
-
(2006)
Leukemia
, vol.20
, Issue.11
, pp. 2034-2040
-
-
Fonseca, R.1
Van Wier, S.A.2
Chng, W.J.3
Ketterling, R.4
Lacy, M.Q.5
Dispenzieri, A.6
Bergsagel, P.L.7
Rajkumar, S.V.8
Greipp, P.R.9
Litzow, M.R.10
Price-Troska, T.11
Henderson, K.J.12
Ahmann, G.J.13
Gertz, M.A.14
-
12
-
-
34249652414
-
Kip1-dependent and -independent mechanisms
-
DOI 10.1182/blood-2006-07-038703
-
Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2-and p27Kip1-dependent and-independent mechanisms. Blood 2007; 109: 4995-5001. (Pubitemid 46827799)
-
(2007)
Blood
, vol.109
, Issue.11
, pp. 4995-5001
-
-
Zhan, F.1
Colla, S.2
Wu, X.3
Chen, B.4
Stewart, J.P.5
Kuehl, W.M.6
Barlogie, B.7
Shaughnessy Jr., J.D.8
-
13
-
-
84861488903
-
Prediction of cytogenetic abnormalities with gene expression profiles
-
Zhou Y, Zhang Q, Stephens O, Heuck CJ, Tian E, Sawyer JR et al. Prediction of cytogenetic abnormalities with gene expression profiles. Blood 2012; 119: e148-e150.
-
(2012)
Blood
, vol.119
-
-
Zhou, Y.1
Zhang, Q.2
Stephens, O.3
Heuck, C.J.4
Tian, E.5
Sawyer, J.R.6
|